Skip to main content
SpringerLink
Log in
Book cover

Small Molecules in Oncology pp 259–267Cite as

Ibrutinib

  • Chapter
  • First Online:

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 201))

Abstract

Abnormal B-cell receptor (BCR) signaling is a key mechanism of disease progression in B-cell malignancy. Bruton’s tyrosine kinase (BTK) has a pivotal role in BCR signaling. Ibrutinib (PCI-32765) is a novel agent which serves as a covalent irreversible inhibitor of BTK. It is characterized by high selectivity for BTK and high potency. Preliminary data from phase I and ongoing phase II trials have proven very promising so far. It suggests the substance has high efficacy in B-cell malignancies such as chronic lymphocytic leukemia (CLL); diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantel cell lymphoma (MCL), and multiple myeloma (MM) and is very well tolerable. Most notably, the substance does not cause myelosuppression. This chapter discusses structure, mechanism of action, and toxicities of ibrutinib and also presents important preclinical and clinical data. Phase III trials will have to determine the definite role of ibrutinib in clinical practice but the data available so far suggests it may be a powerful new weapon in the battle against B-cell malignancies.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Advani RH et al (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 31(1):88–94

    Article  CAS  PubMed  Google Scholar 

  • Bruton OC et al (1952) Absence of serum gamma globulins. AMA Am J Dis Child. 84(5):632–636

    CAS  PubMed  Google Scholar 

  • Burger JA et al (2012) The BTK inhibitor ibrutinib (PCI-32765) in combination with Rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia. In: Blood 120:Abstract 187

    Google Scholar 

  • Burger JA (2013) Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood 121(9):1501–1509

    Article  CAS  PubMed  Google Scholar 

  • Byrd JC et al (2012) The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) promotes high response rate, durable remissions, and is tolerable in treatment naïve (TN) and relapsed or refractory (RR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients including patients with high-risk (HR) disease: new and updated results of 116 patients in a phase Ib/II Study. Blood 120:Abstract 189

    Google Scholar 

  • Chang BY et al (2011) The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther 13(4):R115

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Cheson BD et al (2012) Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 30(23):2820–2822

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Chiorazzi N et al (2005) Chronic lymphocytic leukemia. N Engl J Med 352(8):804–815

    Article  CAS  PubMed  Google Scholar 

  • Dasmahapatra G et al (2013) The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. Br J Haematol 161(1):43–56

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Davis RE et al (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463(7277):88–92

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • de Gorter DJ et al (2007) Bruton’s tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity 26(1):93–104

    Article  PubMed  Google Scholar 

  • de Rooij MF et al (2012) The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119(11):2590–2594

    Article  PubMed  Google Scholar 

  • Di Paolo JA et al (2011) Specific BTK inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol 7(1):41–50

    Article  PubMed  Google Scholar 

  • Dühren-von Minden M et al (2012) Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 489(7415):309–312

    Article  PubMed  Google Scholar 

  • Farooqui M et al (2012) 1789 ibrutinib (PCI 32765) rapidly improves platelet counts in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients and has minimal effects on platelet aggregation. Blood 120:Abstract 1789

    Google Scholar 

  • Fowler NH (2012) The Bruton’s tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma. Blood 120:Abstract 156

    Google Scholar 

  • Herman SE et al (2011) Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 117(23):6287–6296

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Honigberg LA et al (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 107(29):13075–13080

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Jaglowski SM, Jones JA, Flynn JM et al (2012) A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. J Clin Oncol 30:(suppl: Abstr 6508)

    Google Scholar 

  • Janeway et al (2005) Immunobiology, 6th edn. Garland science Publishing, New York

    Google Scholar 

  • Liu J et al (2006) Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo. Blood 108(8):2596–2603

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • O’Brien SM et al (2012) Combination of the Bruton’s tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): interim results of a phase Ib/II study. J Clin Oncol 30:(suppl: Abstr 6515)

    Google Scholar 

  • Ortolano S et al (2006) Roles for phosphoinositide 3-kinases, Bruton’s tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing. Eur J Immunol 36(5):1285–1295

    Article  CAS  PubMed  Google Scholar 

  • Pan Z et al (2007) Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase. ChemMedChem 2(1):58–61

    Article  CAS  PubMed  Google Scholar 

  • Ponader S et al (2012) The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119(5):1182–1189

    Article  CAS  PubMed  Google Scholar 

  • Quek LS et al (1998) A role for Bruton’s tyrosine kinase (Btk) in platelet activation by collagen. Curr Biol 8(20):1137–1140

    Article  CAS  PubMed  Google Scholar 

  • Rushworth SA et al (2013) BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB. Cell Signal 25(1):106–112

    Article  CAS  PubMed  Google Scholar 

  • Satterthwaite AB et al (2000) The role of Bruton’s tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev 175:120–127

    Article  CAS  PubMed  Google Scholar 

  • Schwamb J et al (2012) B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides. Blood 120(19):3978–3985

    Article  CAS  PubMed  Google Scholar 

  • Stevenson FK et al (2011) B-cell receptor signaling in chronic lymphocytic leukemia. Blood 118(16):4313–4320

    Article  CAS  PubMed  Google Scholar 

  • Tai YT et al (2012) Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 120(9):1877–1887

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Vij R et al (2012) Early changes in cytokines, chemokines and indices of bone metabolism in a phase 2 study of the Bruton tyrosine kinase (Btk) inhibitor, ibrutinib (PCI-32765) in patients with relapsed or relapsed/refractory multiple myeloma (MM). Blood 120:Abstract 4039

    Google Scholar 

  • Wang M et al (2012) Interim results of an international, multicenter, phase 2 study of Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), in relapsed or refractory mantle cell lymphoma (MCL): durable efficacy and tolerability with longer follow-up. Blood 120:(Abstract 904)

    Google Scholar 

  • Wilson WH (2012) The Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. Blood 120:(Abstract 686)

    Google Scholar 

  • Woyach JA et al (2012) The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 120(6):1175–1184

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Yang Y et al (2012) Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 21(6, 19):723–737

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universität Heidelberg, Heidelberg, Germany

    Mark-Alexander Schwarzbich & Matthias Witzens-Harig

Authors
  1. Mark-Alexander Schwarzbich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthias Witzens-Harig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthias Witzens-Harig .

Editor information

Editors and Affiliations

  1. Cancer Center Heilbronn-Franken, SLK-Kliniken Heilbronn GmbH Medizinische Klinik III, Heilbronn, Germany

    Uwe M. Martens

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Schwarzbich, MA., Witzens-Harig, M. (2014). Ibrutinib. In: Martens, U. (eds) Small Molecules in Oncology. Recent Results in Cancer Research, vol 201. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54490-3_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-54490-3_17

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-54489-7

  • Online ISBN: 978-3-642-54490-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation